Toboroz
Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis
NCT07686081· 3. fázis· Vanda Pharmaceuticals· Forrás
Még nem toboroz
Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.
NCT07757412· 2. fázis· Odense University Hospital· Forrás
Toboroz
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087· 3. fázis· Boehringer Ingelheim· Forrás
Még nem toboroz
Does a higher radiation dose prolong survival of patients with limited-stage small cell lung cancer receiving immunotherapy after chemotherapy and radiation therapy (DAHRTS trial)?
2026-525513-31-00· 3. fázis· Norges Teknisk-Naturvitenskapelige Universitet NTNU· Forrás
Toboroz
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes
NCT07216235· 3. fázis· Zydus Therapeutics Inc.· Forrás
Toboroz
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
NCT07286058· 3. fázis· Takeda· Forrás
Toboroz
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
NCT07223814· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Még nem toboroz
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
2025-522471-28-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Toboroz
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
NCT06931717· 3. fázis· ETOP IBCSG Partners Foundation· Forrás
Toboroz
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
NCT06932562· 3. fázis· European Myeloma Network B.V.· Forrás
Toboroz
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390· 3. fázis· Eli Lilly and Company· Forrás
Toboroz
A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation
NCT06243731· Takeda· Forrás
Contact: Kadri Lilienthal (principal investigator)
Toboroz
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.
2024-512753-24-00· 3. fázis· Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting· Forrás
Toboroz
Surgical vs Transcatheter Aortic Valve Replacement in YOUNG Patients
NCT06861361· Ceric Sàrl· Forrás
Contact: Peep Laanmets, MD
Toboroz
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
NCT06652438· 3. fázis· Stichting Hemato-Oncologie voor Volwassenen Nederland· Forrás
Fut, nem toboroz
Polygenic Risk Driven Pragmatic Statin Trial for Heart Disease Prevention
NCT06820086· 4. fázis· Mikk JÜRISSON· Forrás
Fut, nem toboroz
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs
2024-516213-20-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Fut, nem toboroz
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483· 3. fázis· Takeda· Forrás
Toboroz
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
NCT06284317· 3. fázis· ETOP IBCSG Partners Foundation· Forrás
Fut, nem toboroz
Randomized Double-Blind Trial on Safety and Efficacy of Nanordica Advanced Antibacterial Wound Dressing for Diabetic Foot Ulcer
NCT06667752· Nanordica Medical OU· Forrás
Fut, nem toboroz
DART (19-14434)
Durvalumab (MEDI4736) After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study investigating PDL1 positive and negative patients
NCT04392504· 1/2. fázis· Oslo University Hospital Hf· Forrás
Fut, nem toboroz
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542· 2. fázis· AbbVie· Forrás
Fut, nem toboroz
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06564142· 3. fázis· Alpine Immune Sciences Inc, A Subsidiary of Vertex· Forrás
Toboroz
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649· 3. fázis· Amgen· Forrás
Fut, nem toboroz
TALTEC: A phase II study measuring MRD negativity after bispecific T-cell redirectors TALquetamab and TEClistamab consolidation as part of first line treatment in transplant eligible multiple myeloma patients
2023-508212-38-00· 2. fázis· North Estonia Medical Centre Foundation· Forrás
Fut, nem toboroz
LSTA1 for subjects with newly diagnosed Glioblastoma Multiforme when added to standard of care (temozolomide) versus temozolomide
2023-506813-23-00· 2. fázis· Tartu University Hospital· Forrás
Toboroz
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
NCT06077760· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200· 3. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05843643· 3. fázis· AbbVie· Forrás
Toboroz
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
NCT05712200· 3. fázis· Anthos Therapeutics, Inc.· Forrás
Toboroz
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
NCT04628026· 3. fázis· University of Ulm· Forrás
Fut, nem toboroz
Is there a survival benefit of administering thoracic radiotherapy concurrently with immunnotherapy and chemotherapy for patients with extensive stage small-cell lung cancer?
NCT05223647· 3. fázis· Norwegian University Of Science And Technolology· Forrás
Fut, nem toboroz
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
NCT05152147· 3. fázis· Jazz Pharmaceuticals· Forrás
Fut, nem toboroz
Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients
NCT04717700· 2. fázis· Ida Bruun Kristensen· Forrás
Fut, nem toboroz
The SABLe study
2024-512276-35-00· 2. fázis· Odense University Hospital· Forrás
Fut, nem toboroz
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
NCT04882098· 3. fázis· Janssen Research & Development, LLC· Forrás
Meghívásos bevonás
A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®
NCT04574076· Novo Nordisk A/S· Forrás
Fut, nem toboroz
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
NCT04432584· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma
NCT04332822· 3. fázis· Nordic Lymphoma Group· Forrás
Toboroz
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
NCT04307576· 3. fázis· Mats Heyman· Forrás
Fut, nem toboroz
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
NCT04380636· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
NCT04241185· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Randomised Evaluation of COVID-19 Therapy
NCT04381936· 3. fázis· University of Oxford· Forrás
Fut, nem toboroz
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
NCT04082429· 3. fázis· Novo Nordisk A/S· Forrás
Fut, nem toboroz
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
NCT03950232· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
NCT03675308· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
NCT03671148· 3. fázis· AbbVie· Forrás
Showing 50 of 52.